Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolism in patients undergoing surgery or experiencing acute clotting events.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across multiple continents and reliable.

Innohep, a low molecular weight heparin, is used in the management of venous thromboembolic conditions.

- Deep vein thrombosis (DVT) prophylaxis: reduces the risk of clot formation in surgical patients. - Acute deep vein thrombosis treatment: facilitates resolution of existing thrombi and prevents extension. - Pulmonary embolism treatment: decreases embolic burden and improves pulmonary circulation.

The most frequently reported reactions to Innohep are related to its anticoagulant activity and injection site.

Common Side Effects: - Injection site erythema or pain - Bruising or hematoma at the injection site - Minor bleeding such as epistaxis or gum bleeding - Nausea - Headache

Serious or Rare Side Effects: - Major hemorrhage (intracranial or gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Spinal or epidural hematoma - Severe allergic reactions including anaphylaxis - Elevated liver enzymes

When using Innohep, clinicians should consider several safety factors to minimize bleeding risk and other complications.

- Renal impairment: assess renal function and monitor anti‑Xa levels if indicated. - Hepatic dysfunction: evaluate liver enzymes before initiation. - Concomitant anticoagulants or antiplatelet agents: increased bleeding risk, use with caution. - Recent surgery or trauma: postpone administration until hemostasis is secured. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Store at ambient temperature: keep in original container, protect from moisture and light.

Innohep may interact with other medicines that affect haemostasis or drug metabolism.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive bleeding risk. - Systemic thrombolytic therapy: heightened risk of severe hemorrhage. - High‑dose antiplatelet agents (e.g., clopidogrel, ticagrelor): may potentiate bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: may modestly raise bleeding tendency. - ACE inhibitors: monitor for rare cases of increased anticoagulant effect.